Carlos Gomez-Roca

Carlos Gomez-Roca

UNVERIFIED PROFILE

Are you Carlos Gomez-Roca?   Register this Author

Register author
Carlos Gomez-Roca

Carlos Gomez-Roca

Publications by authors named "Carlos Gomez-Roca"

Are you Carlos Gomez-Roca?   Register this Author

45Publications

1920Reads

14Profile Views

Sicca Syndrome Induced by Immune Checkpoint Inhibitor Therapy: Optimal Management Still Pending.

Oncologist 2020 Feb 6;25(2):e391-e395. Epub 2019 Nov 6.

Department of Oral Medicine, Institut Universitaire du Cancer Toulouse Oncopole, Toulouse, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1634/theoncologist.2019-0467DOI Listing
February 2020

Phase I dose-escalation trial of afatinib, an irreversible ErbB family blocker, in combination with gemcitabine or docetaxel in patients with relapsed or refractory solid tumors.

Invest New Drugs 2018 12 29;36(6):1044-1059. Epub 2018 May 29.

Institut Universitaire du Cancer de Toulouse-Oncopole and Institut Claudius Regaud, 1 avenue Irène Joliot-Curie, 31059, Toulouse Cedex 9, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10637-018-0601-1DOI Listing
December 2018

Phase I trial of afatinib and 3-weekly trastuzumab with optimal anti-diarrheal management in patients with HER2-positive metastatic cancer.

Cancer Chemother Pharmacol 2018 12 22;82(6):979-986. Epub 2018 Oct 22.

Institut Universitaire du Cancer de Toulouse, Oncopôle, 1 avenue Irène Joliot-Curie, 31059, Toulouse Cedex 9, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-018-3689-2DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6267664PMC
December 2018

Continuous Infusion of Cilengitide Plus Chemoradiotherapy for Patients With Stage III Non-Small-cell Lung Cancer: A Phase I Study.

Clin Lung Cancer 2018 05 21;19(3):e277-e285. Epub 2017 Nov 21.

Department of Radiation Oncology, Institut Claudius Regaud/Institut Universitaire du Cancer de Toulouse, Oncopole, Toulouse, France; Université Paul Sabatier, Toulouse, France; INSERM U1037, Centre de Recherche Contre le Cancer de Toulouse, Toulouse, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cllc.2017.11.002DOI Listing
May 2018

Phase 1, open-label, dose-escalation study of sorafenib in combination with eribulin in patients with advanced, metastatic, or refractory solid tumors.

Cancer Chemother Pharmacol 2018 04 21;81(4):727-737. Epub 2018 Feb 21.

Department of Oncology and Hematology, Charité-Universitätsmedizin Berlin, Hindenburgdamm 30, 12209, Berlin, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-018-3540-9DOI Listing
April 2018

Safety and Efficacy of Pembrolizumab in Advanced, Programmed Death Ligand 1-Positive Cervical Cancer: Results From the Phase Ib KEYNOTE-028 Trial.

J Clin Oncol 2017 Dec 2;35(36):4035-4041. Epub 2017 Nov 2.

Jean-Sebastien Frenel, Institut de Cancerologie de l'Ouest, Centre René Gauducheau, Saint-Herblain; Christophe Le Tourneau, Institut Curie, Paris and Saint-Cloud, and Institut National de la Santé et de la Recherche Médicale U900 Research Unit, Saint-Cloud; Carlos Gomez-Roca, Institut Claudius Regaud, Toulouse; Andrea Varga, Gustave Roussy, Villejuif, France; Bert O'Neil, Indiana University Health University Hospital, Indianapolis, IN; Patrick A. Ott, Dana-Farber Cancer Institute, Boston, MA; Sarina A. Piha-Paul, The University of Texas MD Anderson Cancer Center, Houston, TX; Emilie M.J. van Brummelen, The Netherlands Cancer Institute, Amsterdam, Netherlands; Hope S. Rugo, University of California, San Francisco, San Francisco, CA; and Shari Thomas, Sanatan Saraf, and Reshma Rangwala, Merck & Co., Inc., Kenilworth, NJ.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.74.5471DOI Listing
December 2017

Concurrent radiotherapy for patients with metastatic melanoma and receiving anti-programmed-death 1 therapy: a safe and effective combination.

Melanoma Res 2017 10;27(5):485-491

Departments of aRadiation OncologybBiostatistics, Claudius Regaud InstitutecDepartment of Medical OncologydDepartment of Dermatology, Toulouse University Hospital, Larrey Hospital, The Toulouse University Institute of Cancer, Toulouse, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CMR.0000000000000386DOI Listing
October 2017

Severe Onycholysis and Eyelash Trichomegaly Following Use of New Selective Pan-FGFR Inhibitors.

JAMA Dermatol 2017 07;153(7):723-725

Departments of Oncodermatology and Clinical Research, Institut Claudius Regaud, Institut Universitaire du Cancer, Toulouse Oncopole, France.

View Article

Download full-text PDF

Source
http://archderm.jamanetwork.com/article.aspx?doi=10.1001/jam
Publisher Site
http://dx.doi.org/10.1001/jamadermatol.2017.0500DOI Listing
July 2017

Prediction of Everolimus Toxicity and Prognostic Value of Skeletal Muscle Index in Patients With Metastatic Renal Cell Carcinoma.

Clin Genitourin Cancer 2017 06 1;15(3):350-355. Epub 2017 Feb 1.

Oncology Department, European Georges Pompidou Hospital, René Descartes University, Paris, France; Association pour la Recherche sur les Thérapeutiques Innovantes en Cancérologie, Paris, France; U790 PARCC, European Georges Pompidou Hospital, René Descartes University, Paris, France. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clgc.2017.01.022DOI Listing
June 2017

Bromodomain inhibitor OTX015 in patients with acute leukaemia: a dose-escalation, phase 1 study.

Lancet Haematol 2016 Apr 18;3(4):e186-95. Epub 2016 Mar 18.

Hôpital Saint Louis, Assistance Publique-Hôpitaux de Paris, Paris, France; EA-3518, Institut Universitaire d'Hématologie, Université Paris Diderot, Paris, France. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S2352-3026(15)00247-1DOI Listing
April 2016

Emerging new anticancer therapies in 2013.

Curr Opin Oncol 2014 May;26(3):357-62

Departement of Medical Oncology, Institut Claudius Regaud, Toulouse, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CCO.0000000000000081DOI Listing
May 2014

Clinical benefit for patients with non-small cell lung cancer enrolled in phase I trials.

Onkologie 2013 13;36(6):357-62. Epub 2013 May 13.

SITEP (Service des Innovations Therapeutiques Precoces), Department of Medicine, Institut Gustave Roussy, Paris XI University, Villejuif, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000351257DOI Listing
January 2014

Tumor growth rate is an early indicator of antitumor drug activity in phase I clinical trials.

Clin Cancer Res 2014 Jan 15;20(1):246-52. Epub 2013 Nov 15.

Authors' Affiliations: Departments of Medical Oncology, Biostatistics and Epidemiology, Innovative Therapeutics and Early Drug Development, Radiology, and Radiotherapy; INSERM U981, University Paris Sud, Gustave Roussy, Villejuif, France; and Sage Bionetworks, Fred Hutchinson Cancer Research Center, Seattle, Washington.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-13-2098DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3947306PMC
January 2014

[Role of high-throughput sequencing in oncology].

Bull Cancer 2013 Mar;100(3):295-301

Institut Curie, département d'oncologie médicale, 26, rue d'Ulm, 75248 Paris cedex 05, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1684/bdc.2013.1717DOI Listing
March 2013

Reappraisal of treatment-induced renal dysfunction in patients receiving antiangiogenic agents in phase I trials.

Invest New Drugs 2012 Jun 21;30(3):1116-20. Epub 2011 Apr 21.

SITEP (Service des Innovations Therapeutiques Precoces), Department of Medicine, Institut Gustave Roussy, Paris XI University, 114 rue Edouard Vaillant, 94805, Villejuif, France.

View Article

Download full-text PDF

Source
http://link.springer.com/content/pdf/10.1007/s10637-011-9671
Web Search
http://link.springer.com/10.1007/s10637-011-9671-z
Publisher Site
http://dx.doi.org/10.1007/s10637-011-9671-zDOI Listing
June 2012

Prognostic value of circulating VEGFR2+ bone marrow-derived progenitor cells in patients with advanced cancer.

Eur J Cancer 2012 Jun 25;48(9):1354-62. Epub 2012 Feb 25.

Department of Medicine, Institut de Cancérologie Gustave Roussy, 114 rue Edouard Vaillant, 94805 Villejuif, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2012.01.021DOI Listing
June 2012

Tumour growth rates and RECIST criteria in early drug development.

Eur J Cancer 2011 Nov 15;47(17):2512-6. Epub 2011 Jul 15.

Service des Innovations Thérapeutiques Précoces (SITEP), Département de Medecine, Institut Gustave Roussy, Villejuif, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2011.06.012DOI Listing
November 2011

Phase I trials of molecularly targeted agents: should we pay more attention to late toxicities?

J Clin Oncol 2011 May 28;29(13):1728-35. Epub 2011 Mar 28.

Royal Marsden Hospital and The Institute of Cancer Research, Sutton, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2010.31.9236DOI Listing
May 2011

Dysphonia induced by vascular endothelium growth factor/vascular endothelium growth factor receptor inhibitors.

Invest New Drugs 2010 Dec 16;28(6):884-6. Epub 2009 Sep 16.

Department of Otolaryngology Head & Neck Surgery, Institut Gustave Roussy, Paris, France.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s10637-009-9314-9
Publisher Site
http://dx.doi.org/10.1007/s10637-009-9314-9DOI Listing
December 2010

Reversible cardiogenic shock following 5-fluorouracil infusion.

Invest New Drugs 2010 Aug 5;28(4):531-3. Epub 2009 Jun 5.

Phase I unit (SITEP), Department of Medicine, Institut Gustave Roussy, 94805, Villejuif, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10637-009-9271-3DOI Listing
August 2010

Pemetrexed-induced pneumonitis: a case report.

Clin Lung Cancer 2009 Sep;10(5):364-6

Department of Medicine, SITEP, Institut Gustave Roussy, Universite Paris XI, and Department of Pneumology, Hôpital Tenon, Marie Curie, Paris VI, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3816/CLC.2009.n.050DOI Listing
September 2009

[Prognostic risk factors for serious complications in an inpatient population with neutropenia at the onset of a febrile episode].

Medicina (B Aires) 2006 ;66(5):385-91

Departamento de Medicina Interna, Instituto Universitario CEMIC, Buenos Aires, Argentina.

View Article

Download full-text PDF

Source
August 2007